MYOV Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 mar 2023 @ 22:01):

Stats
Dagens volum	2.26M
Gjennomsnittsvolum	1.09M
Markedsverdi	2.62B
EPS	$0 ( 2023-07-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.05
ATR14	$0.0590 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-10	Valente Nancy	Sell	3 673	Common Shares
2023-03-10	Valente Nancy	Sell	36 892	Stock Options (Right to Buy)
2023-03-10	Potter Myrtle S	Sell	3 673	Common Shares
2023-03-10	Potter Myrtle S	Sell	45 000	Stock Options (Right to Buy)
2023-03-10	Potter Myrtle S	Sell	58 608	Stock Options (Right to Buy)

INSIDER POWER
71.95
Last 100 transactions
Buy: 52 768 183 \| Sell: 8 648 674

Volum Korrelasjon

Lang: 0.03 (neutral)

Kort: -0.75 (moderate negative)

Signal:(61.005) Neutral

Myovant Sciences Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Myovant Sciences Ltd Korrelasjon - Valuta/Råvare

-0.25
( neutral )

0.28
( neutral )

0.00
( neutral )

-0.10
( neutral )

-0.79
( moderate negative )

0.31
( neutral )

Myovant Sciences Ltd Økonomi

Annual	2022
Omsetning:	$230.97M
Bruttogevinst:	$179.42M (77.68 %)
EPS:	$-2.22

FY	2022
Omsetning:	$230.97M
Bruttogevinst:	$179.42M (77.68 %)
EPS:	$-2.22

FY	2021
Omsetning:	$59.32M
Bruttogevinst:	$57.35M (96.69 %)
EPS:	$-2.83

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.37

Financial Reports:

No articles found.

Myovant Sciences Ltd

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.